ATF3 Repression of BCL-X L Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non-small cell lung cancer, and estrogen receptor-positive breast...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 23; no. 18; p. 5573
Main Authors:	Chüeh, Anderly C, Tse, Janson W T, Dickinson, Michael, Ioannidis, Paul, Jenkins, Laura, Togel, Lars, Tan, BeeShin, Luk, Ian, Davalos-Salas, Mercedes, Nightingale, Rebecca, Thompson, Matthew R, Williams, Bryan R G, Lessene, Guillaume, Lee, Erinna F, Fairlie, Walter D, Dhillon, Amardeep S, Mariadason, John M
Format:	Journal Article
Language:	English
Published:	United States 15-09-2017
Subjects:	Activating Transcription Factor 3 - genetics Activating Transcription Factor 3 - metabolism Animals Antineoplastic Agents - pharmacology Apoptosis - drug effects Apoptosis - genetics bcl-X Protein - genetics bcl-X Protein - metabolism Cell Line, Tumor Disease Models, Animal Drug Resistance, Neoplasm Gene Expression Gene Expression Regulation, Neoplastic - drug effects Genes, Immediate-Early Genes, Reporter Histone Deacetylase Inhibitors - pharmacology Humans Mice Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - pathology RNA Interference Tumor Burden - drug effects Xenograft Model Antitumor Assays
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!